Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aimed to

1. compare the eradication rates and long term re-infection rates of sequential therapy for 14 days versus bismuth quadruple therapy for 10 days in the first line and second line treatment

2. assess the impact of antibiotic resistance and CYP2C19 polymorphism on the eradication rate of these regimens

3. assess the impact of these eradication regimens on the antibiotic resistance and microbiota of the gut flora

4. assess the impact of eradication therapy on the metabolic factors

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Taiwan University Hospital
• Collaborators: Chiayi Christian Hospital; E-DA Hospital; Kaohsiung Medical University; Mackay Memorial Hospital; National Taiwan University Hospital Hsin-Chu Branch; Taipei Veterans General Hospital, Taiwan
• Treatments: Bismuth

Criteria

Inclusion Criteria:

1. H. pylori infected patients naïve to eradication therapies will be eligible in this study.

Exclusion Criteria:

1. children and teenagers aged less than 20 years,

2. history of gastrectomy,

3. gastric malignancy, including adenocarcinoma and lymphoma,

4. previous allergic reaction to antibiotics (bismuth, amoxicillin, metronidazole, clarithromycin, tetracycline) and PPI (esomeprazole),

5. contraindication to treatment drugs,

6. pregnant or lactating women,

7. severe concurrent disease,

8. concomitant use of clopidogrel, or (9) Unwilling to accept random assignment of subjects